Literature DB >> 16988046

A specific survival response in dopamine neurons at most risk in Parkinson's disease.

Sachiko Murase1, Ronald D McKay.   

Abstract

The specific expression of fibroblast growth factor 20 (FGF-20) in the adult substantia nigra and the association between FGF-20 mutations and Parkinson's disease provoked exploration of the function of this growth factor. We show by gain- and loss-of-function in vitro experiments that FGF-20 promotes survival and stimulates dopamine (DA) release in a calbindin-negative subset of cells that are preferentially lost in Parkinson's disease. FGF-20 selectively activates tyrosine hydroxylase in calbindin-negative neurons. In the adult substantia nigra, calbindin-negative neurons specifically express high levels of FGFR1 (FGF receptor 1). These data show that FGF signals to elevate DA levels and protect the specific midbrain neuron type at most risk in Parkinson's patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988046      PMCID: PMC6674460          DOI: 10.1523/JNEUROSCI.2745-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  29 in total

1.  Genetic variation in FGF20 modulates hippocampal biology.

Authors:  Herve Lemaitre; Venkata S Mattay; Fabio Sambataro; Beth Verchinski; Richard E Straub; Joseph H Callicott; Raja Kittappa; Thomas M Hyde; Barbara K Lipska; Joel E Kleinman; Ronald McKay; Daniel R Weinberger
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

Review 2.  Provisional hypotheses for the molecular genetics of cognitive development: imaging genetic pathways in the anterior cingulate cortex.

Authors:  John Fossella; Jin Fan; Xun Liu; Kevin Guise; Karin Brocki; Patrick R Hof; Raja Kittappa; Ronald McKay; Michael Posner
Journal:  Biol Psychol       Date:  2007-12-28       Impact factor: 3.251

3.  Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease.

Authors:  Rosario Sanchez-Pernaute; Hyojin Lee; Michaela Patterson; Casper Reske-Nielsen; Takahito Yoshizaki; Kai C Sonntag; Lorenz Studer; Ole Isacson
Journal:  Brain       Date:  2008-07-22       Impact factor: 13.501

Review 4.  Molecular mechanisms of dopaminergic subset specification: fundamental aspects and clinical perspectives.

Authors:  Jesse V Veenvliet; Marten P Smidt
Journal:  Cell Mol Life Sci       Date:  2014-07-27       Impact factor: 9.261

5.  In the newborn hippocampus, neurotrophin-dependent survival requires spontaneous activity and integrin signaling.

Authors:  Sachiko Murase; David F Owens; Ronald D McKay
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

Review 6.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

Review 7.  Molecular pathology of the fibroblast growth factor family.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

8.  Quantitative assessment of the association between fibroblast growth factor 20 rs1721100 C/G polymorphism and the risk of sporadic Parkinson's diseases: a meta-analysis.

Authors:  Ze-Gang Ma; Jian Xu; Tian-Wei Liu
Journal:  Neurol Sci       Date:  2014-07-17       Impact factor: 3.307

Review 9.  A dual-hit animal model for age-related parkinsonism.

Authors:  Heather A Boger; Ann-Charlotte Granholm; Jacqueline F McGinty; Lawrence D Middaugh
Journal:  Prog Neurobiol       Date:  2009-10-21       Impact factor: 11.685

Review 10.  Assessing the molecular genetics of the development of executive attention in children: focus on genetic pathways related to the anterior cingulate cortex and dopamine.

Authors:  K Brocki; S M Clerkin; K G Guise; Jin Fan; J A Fossella
Journal:  Neuroscience       Date:  2009-01-20       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.